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Randomized controlled clinical trials remain the best
method for minimizing bias when evaluating derma-
tological treatments. Many dermatologic clinical trials
have suffered from small sample sizes, selective
reporting of outcomes, publication bias, poor report-
ing, and heterogeneous outcomes that have ham-
pered comparability—deficiencies that can be
overcome by adopting good trial planning and
reporting practice encouraged by this journal.
Although a profusion of explanatory placebo-con-
trolled studies have contributed little to decision
making in the clinical setting, some comparative
effectiveness trials such as the use of topical corti-
costeroids for pemphigoid may have played a pivotal
role in improving the well-being of dermatological
patients. Systematic reviews (SRs) of clinical trials
strive to organize the entire body of evidence while
minimizing bias so that policy makers and guideline
developers can base their recommendations on the
appropriate strength and level of evidence. In derma-
tology, SRs, such as those undertaken by the
Cochrane Collaboration, have produced clear clinical
messages despite conflicting individual studies, and
also play a key role in identifying research gaps.
Future challenges include optimizing the use of
research resources, adopting methodological devel-
opments in health technology assessment, and pro-
spective registration and complete reporting of all
study results.
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THE PRIMACY OF SYSTEMATIC REVIEWS AND
RANDOMIZED CONTROLLED CLINICAL TRIALS
Systematic reviews (SRs) and randomized controlled clinical
trials occupy a position at the top of the evidence hierarchy
that informs evidence-based practice (Oxford Centre for
Evidence-based Medicine—Levels of Evidence, http://
www.cebm.net/index.aspx?o=1025, accessed 22 July 2011).
Both forms of health technology assessment hold potential
to discover new scientific information that may be crucial
for informing shared decision making with dermatologic
patients, as well as providing policy makers and managed
care organizations with information on the effects and cost
effectiveness of alternative treatment approaches. Yet,
dermatology has lagged behind some developments in these
forms of research to some extent. In this article, we begin by
describing the concept of pragmatic clinical trials, and then
cite examples of how such trials have led to important
advances in the care of dermatological patients. We follow
with a commentary on the contribution of SRs of clinical trials
in dermatology, and whether such reviews really inform
clinical practice as opposed to always concluding with that
vacuous phrase ‘‘more research is needed’’ (Godlee, 2010).
Finally, we introduce methodological developments in the
field and identify the barriers to conducting good clinical
trials and SRs. We close by suggesting solutions for improving
these forms of health technology assessment within the
context of comparative effectiveness research (CER).
PART 1: RANDOMIZED CONTROLLED CLINICAL
TRIALS IN DERMATOLOGY
What are they?
Although the term ‘‘clinical trial’’ is sometimes used loosely
to mean any form of clinical study, the International
Committee of Medical Journal Editors defines a clinical trial
as research that prospectively assigns human participants to
intervention and concurrent comparison groups to study the
cause-and-effect relationship between a medical intervention
and a health outcome (De Angelis et al., 2004). Interventions
can include surgical procedures, behavior modifications, and
process-of-care changes, and not just drugs. Explanatory trials
are designed to answer the question: ‘‘Can this intervention
work?’’ They are carried out under ideal conditions, with
highly selected patients, drug doses, and placebo or vehicle
groups, and typically contain short-term efficacy or surrogate
efficacy measures. Pragmatic trials, on the other hand, aim to
answer the question: ‘‘Does this treatment work in real
clinical practice?’’ (Roland and Torgerson, 1998). Pragmatic
trials are usually larger and include study participants who
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are much more similar to those encountered in everyday
clinical practice, and control groups typically include those
using existing active treatments. The distinction is helpful
when designing and interpreting a study, but it is not a rigid
dichotomy, and it is more helpful to think of trials as
belonging to an explanatory to pragmatic continuum (Thorpe
et al., 2009).
Have dermatologic clinical trials informed patient care?
With regard to the profusion of placebo-controlled studies,
the answer is ‘‘probably not very much.’’ For example, there
have been at least 14 randomized controlled trials (RCTs) of
topical pimecrolimus for atopic dermatitis (Ashcroft et al.,
2007). Two or three placebo RCTs of a new drug are
appropriate for licensing purposes or for exploring use in
children and different ethnic groups or body locations, but
the ethics and usefulness of conducting 14 such studies is
questionable. Few doctors prescribe placebos or vehicles
alone, and what most clinicians want to know is how new
therapies compare with existing best therapies in terms of
efficacy, adverse effects, tolerability, and cost effectiveness in
real-world settings. Such is the underlying concept of CER
(Agency for Healthcare Research and Quality, http://www.
effectivehealthcare.ahrq.gov/index.cfm/what-is-comparative-
effectiveness-research1/, accessed 22 July 2011), which has
benefited from significant funding from the US Government
through the American Recovery and Reinvestment Act of
2009 (Sox and Greenfield, 2009). Poorly reported trials have
similarly failed patients and the scientific community. Many
dermatological RCTs omit essential data such as how many
participants withdrew and whether randomization was
adequately concealed to minimize selection bias (Hoare
et al., 2000; Naldi et al., 2003; van Coevorden et al., 2004;
Alvarez et al., 2009; Ingram et al., 2010). As shown in
Table 1, it is often impossible to tell whether poor reporting is
an indicator of poor quality (Williams, 2010).
Yet, despite these shortcomings, there are some out-
standing examples of dermatological clinical trials that have
contributed positively to help patient care. Here, we describe
five dermatology trials that illustrate different types of patient
benefits.
Reducing mortality from adverse effects. Oral prednisolone
has been a popular treatment for bullous pemphigoid for
many years. Although prednisolone usually does a good job
at controlling blisters, there are significant concerns about its
safety, especially in an elderly population that pemphigoid
typically affects (Kirtschig et al., 2010). Moved by the
possibility that dermatologists might be inadvertently increas-
ing patient mortality at the expense of initial blister control,
Joly et al. (2002) conducted an RCT comparing topical
clobetasone propionate (40 g day–1) against oral prednisolone
(0.5mg kg–1 for moderate disease and 1mg kg–1 for severe
disease) and found better efficacy and improved 1-year
survival (76% vs. 58%) in the topical group for those with
extensive disease. In a subsequent trial published in the
Journal of Investigative Dermatology, Joly et al. (2009) went
on to show that smaller quantities of topical clobetasone
(10–30 g per day and tapering over 4 months) was just as
effective as 40 g per day and tapering over 12 months. In
those patients with moderate disease, deaths and life-
threatening events were reduced almost 2-fold with the
milder regimen. Together, these two studies have provided
the basis for a step change in the management of patients
with pemphigoid. Demonstrating impact on clinical care that
is attributable to a single RCT is almost impossible because of
the long period (typically 17 years) taken for new trial
evidence to be adopted into clinical practice (Committee on
Quality of Health Care in America, 2001) and because of the
complexities of other influences such as guidelines and
managed care constraints (Eaglstein, 2010). Nevertheless,
changes in pemphigoid mortality in relation to prescribed
treatment should be measurable over time in sophisticated
database studies (Langan et al., 2008).
Maintaining disease control. One of the most disturbing
findings from an overarching SR of treatments for atopic
dermatitis conducted in 2000 is that most of the 272 included
studies were of short duration, i.e., o6 weeks (Hoare et al.,
2000). Although some short-term studies are clearly needed
to demonstrate the speed of remission in controlling a disease
flare (which none of them did), atopic dermatitis is typically a
chronic disease that lasts for years and that requires long-term
assessment of disease control (Figure 1). In the last decade, it
has been heartening to witness the emergence of longer-term
studies that have explored strategies for maintaining remis-
sion by using regular twice-weekly or ‘‘weekend’’ therapy
with topical corticosteroids (Schmitt et al., 2011b). The
magnitude of effect for such a proactive strategy in preventing
flares is impressive (relative risk of 0.46, 95% confidence
interval 0.38–0.55) for topical fluticasone propionate and is
arguably the single most important breakthrough in the
management of children and adults with moderate-to-severe
atopic dermatitis (Williams, 2011).
Table 1. Trial reporting and study quality may be related but are not necessarily the same
Study quality
Reporting quality Good Flawed
Clear May be helpful for clinical practice At least you can tell it is flawed and make a judgment on utility
Poor A sparkling diamond—but how do you know? Difficult to distinguish from a good but poorly reported study
All poorly reported trials are shown in italics.
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Why empirical reasoning is no longer a valid reason for
trying out new treatments. For many years, empirical
reasoning based on partially elucidated mechanisms was a
cornerstone for justifying giving certain treatments to patients
(Williams and Bigby, 2008). Thus, intravenous lidocaine
stabilized the electrical activity of the heart after myocardial
infarction and made electrocardiograms look smoother. It
became a standard treatment for arrhythmia after infarction
until it was shown that it probably killed more people in the
long run (The Cardia Arrhythmia Suppression Trial II
Investigators, 1992). In dermatology, thalidomide was increas-
ingly being used to treat toxic epidermal necrolysis on the
grounds that toxic epidermal necrolysis is associated with high
levels of tumor necrosis factor-a and that thalidomide inhibits
the actions of tumor necrosis factor-a. A trial of thalidomide
was initiated but stopped early because 10 out of 12 patients
in the thalidomide group died compared with 3 out of 10 on
placebo treatment (Wolkenstein et al., 1998). That trial also
found that those in the thalidomide group had an unexpected
increase in tumor necrosis factor-a levels during treatment.
Perhaps history may be repeating itself with the widespread
current use of intravenous immunoglobulin for toxic epider-
mal necrolysis despite the lack of good evidence (Faye and
Roujeau, 2005). Such examples underline the importance of
trials in determining whether clinical benefit really does occur
with drugs that may appear to be promising on the basis of
basic science and surrogate outcome studies.
The need to compare treatments on a level playing field.
One of the most striking conclusions from reviewing the field
of clinical trials in acne research (Lehmann et al., 2001) is
how few studies compare the main commonly used
treatments head to head under the same conditions. Most
acne RCTs are placebo controlled that are of little help for
dermatologists in deciding whether a new treatment works
any better than existing active treatments. Even when active
comparators are used, they may all differ, or used at a
substandard dose or frequency in order to show the new drug
in a better light (Ingram et al., 2010). Rigorous studies that
compare several commonly used treatments are needed for
CER. Such a study was funded by the UK Government to
compare five commonly used treatments in 649 community
participants with mild-to-moderate facial acne (Ozolins et al.,
2004). The study found that topical benzoyl peroxide and
benzoyl peroxide/erythromycin combinations were of similar
efficacy to oral oxytetracycline and minocycline, and more
importantly that efficacy of the oral antibiotics was compro-
mised by propionibacterial antibiotic resistance—important
findings that underscore the importance of finding nonanti-
biotic approaches to long-term control of acne (Williams
et al., 2011).
Disease prevention. Most dermatologic clinical practices are
preoccupied with individuals with established disease. More
attention could be paid to disease prevention, especially for
life-threatening diseases with established and modifiable risk
factors such as melanoma. An outstanding example of a skin
cancer prevention trial is the Nambour trial conducted in
Queensland, Australia, by Green et al. (1999). Observational
epidemiology studies were unable to separate the determi-
nants of sunscreen use from skin cancer, and hence an
experimental approach was warranted. Using an efficient
factorial design that can answer two questions within the
same study, the team randomized 1,621 residents to one of
four groups: daily application of a sun protection factor 15-
plus sunscreen to exposed areas, and betacarotene supple-
mentation (30mg per day); sunscreen plus placebo tablets;
betacarotene only; or placebo only. Although basal carcino-
ma incidence did not fall, the incidence of squamous cell
carcinoma fell by 39% in the sunscreen group (relative risk
0.61, 95% confidence interval 0.46–0.81), and the effect has
been sustained at 8 years of follow-up (van der Pols et al.,
2006). The study has recently suggested that incidence of
invasive melanoma might also be reduced in the group
encouraged to use daily sunscreens (hazard ratio 0.27; 95%
confidence interval 0.08–0.97) (Green et al., 2011). Although
ambitious and costly in terms of length of follow-up, such
studies have the potential for saving many lives and morbidity
from skin cancer and need to be replicated in other countries
with different levels of ambient UV light.
What are the strengths and limitations of clinical trials?
The overarching strength of clinical trials is their ability to
minimize bias. Randomizing patients to one or more treat-
ments, and then concealing that randomization sequence
from those entering patients into the study, minimizes
Figure 1. Atopic dermatitis is a chronic disease in most sufferers, yet the
majority of clinical trials have looked at short-term outcomes of p6 weeks
(Hoare et al., 2000). Photograph used with permission.
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selection bias. Treating those in one group exactly the same
as the other group minimizes performance bias. Inclusion of a
placebo or vehicle group reduces the potential for informa-
tion bias, and including all those initially randomized in the
final analysis reduces withdrawal bias. Declaring and
publishing success criteria beforehand mitigate against
selective reporting of outcome bias (Chan et al., 2004). Yet,
all of the above, when not performed adequately, are also
limitations of clinical trials. Even when features such as
‘‘double blind’’ are described in studies, it does necessarily
follow that blinding was successful, e.g., when ‘‘double
blind’’ RCTs compare oral retinoids against placebo (Naldi
et al., 2010). Clinical trials are good at estimating efficacy
and effectiveness and common adverse effects, but they are
not good at picking up rare but potentially very serious
drawbacks such as lupus syndrome with minocycline (Ferner
and Moss, 1996) or progressive multifocal leucoencephalo-
pathy with efalizumab (Carson et al., 2009). Clinical trials
cannot answer all clinical questions. Knowledge on patients’
views of treatment requires qualitative research, and studies
of natural history of disease requires cohort studies, and
understanding disease risk factors may require case–control
or longitudinal designs (Sackett and Wennberg, 1997).
Publication bias is another major problem when relying
solely on the results of one large RCT published in a
prominent journal (Ioannidis, 2005), which is partly over-
come through SRs discussed in part 2 of this article.
How can dermatologic clinical trials be improved?
Placing your bet and showing your cards. There are two key
principles. The first is to avoid selective outcome reporting
bias by ‘‘placing your bet.’’ In other words, by prospectively
publishing the clinical trial protocol and primary outcome
measures in a publicly accessible trial register before the
study is completed, others can then judge whether authors
have remained true to their study hypothesis or whether they
have emphasized post hoc findings because the original
results were not positive (Williams and Stern, 2005). The
second is to ‘‘show your hand’’ by reporting all of the
important study features included in the CONSORT (Con-
solidated Standards of Reporting Trials Statement) fully (http://
www.consort-statement.org/, accessed 23 July 2011). The
Journal of Investigative Dermatology is signed up to both of
these important principles (Williams and Stern, 2005;
Williams and Goldsmith, 2006). Outcome measure is another
area that requires further attention in dermatology. Reference
has already been made to outcomes for chronic diseases that
are too short term (Hoare et al., 2000). Methodological work
is required to develop more appropriate long-term outcomes
such as ‘‘well-controlled weeks’’ for diseases like atopic
dermatitis (Langan et al., 2006). Too many outcomes
measures are also a problem. For example, at least 20 named
outcome measures have been published in atopic dermatitis,
yet few have been tested rigorously and even fewer pass
those tests (Schmitt et al., 2007). Bringing international
groups together, such as the HOME (Harmonizing Outcomes
in Eczema) initiative, to agree on core outcome measures is a
challenge that needs to be met by the dermatological
community (Murrell et al., 2008; Schmitt et al., 2011a).
Working together more collaboratively through national and
international dermatology trial networks is also vital if large
numbers of patients with less common skin diseases are to be
studied. The experiences of the UK Dermatology Trials
Network is an example of how such a network has tackled
the lack of evidence in conditions such as cellulitis,
pyoderma gangrenosum, and bullous pemphigoid (Layfield
et al., 2011). Running independent trials more professionally
in collaboration with academic clinical trial units provides
another opportunity to improve the conduct of dermatology
trials (Gluud and Sørensen, 1995). Patient-reported outcomes
have not been a prominent feature of dermatology trials in the
past (Townshend et al., 2008). Patient and public involve-
ment in the design, recruitment, and dissemination of clinical
trials is a neglected facet that requires development if
dermatological trials are to reflect issues that are important
to patients (Hoch et al., 2009).
PART 2: SRS AND DERMATOLOGY
What is an SR?
An SR is a type of publication that identifies and synthesizes
high-quality literature relevant to a research question such as
what is the best therapy for a particular disease. SRs are
collaborative efforts that minimize bias by assessing all
available literature to answer a research question in a
comprehensive prespecified and systematic manner using
clear inclusion and analysis criteria (the protocol). The
authors then perform the review and summarize the data
(the review). SRs are ideally updated with periodic new
literature searches and result summaries to keep the review
results current. SRs comprise the backbone of evidence-based
medicine (http://www.cebm.net/index.aspx?o=1914, ac-
cessed 30 June 2011; Straus et al., 2005). Some funding
organizations and journals encourage an SR on the study
question before funding or publishing a clinical trial (Clarke
et al., 2010).
Although many different people write SRs, the most
prominent, established, and methodologically rigorous
source of SRs is The Cochrane Collaboration (http://www.
cochrane.org/, accessed 30 June 2011; Collier et al., 2006), a
predominantly volunteer group of 420,000 individuals who
produce The Cochrane Database of Systematic Reviews
section of The Cochrane Library (http://www.thecochranelibrary.
com/view/0/index.html, accessed 30 June 2011). The Cochrane
Collaboration has450 review groups including the Skin Group
that has 49 active SRs (http://skin.cochrane.org/our-reviews,
accessed 9 July 2011; Collier et al., 2005a) and the Wounds
Group that has 69 active SRs (http://www2.cochrane.org/
reviews/en/subtopics/96.html, accessed 9 July 2011).
Many steps comprise the writing of a high-quality SR,
including defining the review question, developing criteria
for including studies (healthcare SRs usually stick to just
randomized, controlled, double-blinded clinical trials),
searching for studies, selecting studies, collecting data,
assessing risk of bias in included studies, analyzing data,
addressing reporting bias, presenting results, and drawing
conclusions (Higgins and Green, 2008). Good SRs depend
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heavily on good practices that have been extensively
developed by the Cochrane Collaboration for healthcare
and the Campbell Collaboration for social care issues. SRs
using state-of-the-art methodology can take several years to
complete. To foster dissemination, SRs are sometimes
copublished in shorter formats in academic journals (Greene
et al., 2008) and SRs are frequently cited in professional
medical academy clinical practice guidelines (Table 2). The
DARE (Database of Abstracts of Reviews of Effects) (http://
www.crd.york.ac.uk/CMS2Web/AboutDare.asp, accessed
9 July 2011) compiles the abstracts of high-quality SRs.
Reviews that do not systematically assess the literature are
called narrative reviews (Teagarden, 1989).
What is a meta-analysis?
A meta-analysis is the formal combining of data across
studies. SRs that combine data from different studies are
called meta-analyses. Some meta-analyses may produce
answers to research questions that were not obvious from
looking at individual studies. If the studies are sufficiently
similar, data may be combined either using a fixed effects
model (which assumes that the trials are all assessing exactly
the same quantity and then combines them using weights
determined by the inverse variance of those studies) or more
commonly, a random effects model (a more conservative
approach that assumes that included studies are estimating a
different yet related intervention effect). If the studies appear
different form each other (heterogeneity), sources of such
heterogeneity are sought and explored further by procedures
such as excluding poor-quality studies (a sensitivity analysis).
Further prespecified analyses may also be done on subgroups
of participants such as children versus adults. In meta-
regression, characteristics of the included studies that might
affect the effect size (such as participant age or drug dose) are
explored using a statistical model, and is generally only done
when meta-analyses include 410 studies (Higgins and
Green, 2008).
Because not all SRs uncover high-quality evidence that
can be meaningfully combined from different studies, meta-
analyses comprise a subset of SRs. Over the past decade, the
annual citations of meta-analyses in PubMed are growing
at a rate almost three times faster than that of all publication
types in PubMed (Figure 2). Meta-analyses are also cited
more than other types of articles (Patsopoulos et al., 2005).
Not surprisingly, SRs and meta-analysis, although still not
common, are increasingly published by the Journal of
Table 2. Systematic reviews referenced in current American Academy of Dermatology practice guidelines for acne,
psoriasis, and cutaneous melanoma (25 July 2011)
1. Marqueling AL, Zane LT (2007) Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg
26:210–20.
2. Stern RS, Lunder EJ (1998) Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol
134:1582–5.
3. Bongartz T, Sutton AJ, Sweeting MJ et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies:
systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–85.
4. Ashcroft DM, Po AL, Williams HC et al. (2000) Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque
psoriasis. BMJ 320:963–7.
5. Bruner CR, Feldman SR, Ventrapragada M et al. (2003) A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol
Online J 9:2.
6. Mason J, Mason AR, Cork MJ (2002) Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 146:351–64.
7. Bar Oz B, Hackman R, Einarson T et al. (2001) Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation
71:1051–5.
8. Heydendael VM, Spuls PI, Ten Berge IJ et al. (2002) Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis?
A systematic review and clinical data on trough levels. Br J Dermatol 147:122–9.
9. Faerber L, Braeutigam M, Weidinger G et al. (2001) Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients. Am J Clin Dermatol
2:41–7.
10. Yan J, Chen SL, Wang XL et al. (2008) Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr Dermatol 25:117–20.
11. Spuls PI, Witkamp L, Bossuyt PM et al. (1997) A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 137:943–9.
12. Griffiths CE, Clark CM, Chalmers RJ et al. (2000) A systematic review of treatments for severe psoriasis. Health Technol Assess 4:1–125.
13. Ashcroft DM, Li Wan Po A, Williams HC et al. (2000) Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review
of efficacy and tolerability. Arch Dermatol 2000 136:1536–43.
14. Pollono EN, Lopez-Olivo MA, Lopez JA et al. (2010) A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with
rheumatoid arthritis. Clin Rheumatol 29:947–55.
15. Bafounta ML, Beauchet A, Chagnon S et al. (2004) Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis.
Lancet Oncol 5:673–80.
16. Krug B, Crott R, Lonneux M et al. (2008) Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology 249:836–44.
17. Warycha MA, Zakrzewski J, Ni Q et al. (2009) Meta-analysis of sentinel lymph node positivity in thin melanoma (oor=1mm). Cancer 115:869–79.
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Investigative Dermatology (Hadley et al., 2006; Spuls et al.,
2010).
How do SRs minimize bias?
Perhaps the greatest bias decreased by SRs is that of
publication bias. Rigorous SRs attempt to collect data from
authors that have not been formally published (also known as
‘‘the file drawer problem,’’ named for the presumed final
resting place of many studies with nonsignificant result
findings; Figure 3). By including such data, especially at the
individual patient level, the effects of interventions are often
greatly diminished from those reported in the literature
(Easterbrook et al., 1991). Another bias is database bias.
Because searches using only MEDLINE will result in
recovering B60% of relevant trials (Schlosser et al., 2005),
SRs search many different medical literature databases. SRs
avoid scope bias by including reviews from many geographic
regions, over large relevant time periods without language
restriction (http://www.ncddr.org/kt/products/focus/focus17/,
accessed 13 July 2011).
SRs also provide more complete evidence and a means of
summarizing it with meta-analysis when appropriate while
guarding against the inclusion of duplicated data. To
minimize post hoc analysis bias, SRs should be prospectively
registered with PROSPERO (http://www.openmedicine.ca/
article/viewArticle/464/397/, accessed 7 July 2011; http://
www.crd.york.ac.uk/prospero/, accessed 7 July 2011, Palepu
et al., 2011), or published as a protocol in the Cochrane
Library. Guidelines for highlighting the methodological
deficiencies of included studies such as the Cochrane
Collaboration’s risk of bias tool provide an attractive visual
and informative way of summarizing which study aspects are
at high, low, or unclear risk of bias (http://www.cochrane-
handbook.org/, accessed 30 August 2011). Summarizing the
main findings of complex SRs in a consistent and measured
way that reflects the evidence can also be challenging.
Recent developments such as the GRADE (Grades of
Recommendation, Assessment, Development and Evaluation)
method for constructing summary of findings tables that
incorporates within-study risk of bias (methodological qual-
ity), directness of evidence, heterogeneity, precision of effect
estimates, and risk of publication bias (Guyatt et al., 2011)
offer a potential solution. Quality of reporting of SRs of
therapeutic interventions and diagnostic tests can be assessed
using the PRISMA tool (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) (Higgins and Green,
2008; Liberati et al., 2009).
Another bias much in the news these days is bias because
of conflict of interest or agenda-driven bias; quality SRs must
aim for full disclosure of all stakeholders and full transpar-
ency of methods (Roseman et al., 2011).
Are there any SRs in the Journal of Investigative Dermatology
with surprising results for dermatology clinical research and
medical practice?
With regard to clinical research, an SR of all clinical severity
and outcome measures for psoriasis found 53 separate
clinical measures in the literature with none—not even the
popular Psoriasis Area and Severity Index score—adequately
validated (Spuls et al., 2010). In terms of medical practice,
Hadley et al. (2006) meta-analyzed five randomized double-
blind trials of topical imiquimod versus vehicle in 1,293
patients with actinic keratosis to determine complete
clearance rates, and found a number needed to treat of just
2.2 patients (95% confidence interval 2.0–2.5). Their SR also
directed future research to find optimal dosing to minimize
adverse reactions without decreasing efficacy and to evaluate
long-term efficacy.
What are the strengths and limitations of SRs?
Combining studies in a meta-analysis when possible leads to
greater statistical power for answering a question. SRs help
those interested in answering clinical problems manage
information overload from large numbers of clinical trials
on a particular topic. Adding unpublished and gray literature
such as meeting abstract data to SRs helps determine if a
publication bias exists in the medical literature.
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Figure 2. Annual citations of meta-analyses in PubMed are growing at a rate
almost three times faster than that of all publication types in PubMed.
Source: http://www.ncbi.nlm.nih.gov/pubmed/; accessed 24 June 2011.
Figure 3. File drawers have become the final resting place for many studies
with nonsignificant results. Reproduced with permission.
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Not all SRs are equally reliable, and their reporting could
be improved by a universally agreed upon set of standards
and guidelines (Moher et al., 2007). More than 20% of SRs
need updating within 2 years of publication (Shojania et al.,
2007). Not all SRs include conference abstracts and other less
prominent literature that may increase the comprehensive-
ness of such reviews (Savoie et al., 2003).
Some SRs find ‘‘insufficient evidence’’ to draw conclu-
sions regarding the research question asked. In dermatology,
B40% of Cochrane SRs do find sufficient results to inform
clinical care (Parker et al., 2004). SR may draw attention to
lack of evidence to guide further research. For example, the
Cochrane Review on therapy for molluscum (van der
Wouden et al., 2009) and vitiligo (Whitton et al., 2010)
uncovered no high-quality trials of common therapies in the
literature. Even when SRs do not find evidence to answer the
research question posed, they still help identify research
uncertainties such as those compiled in the DUETs (Database
of Uncertainties about the Effects of Treatments) (http://
www.library.nhs.uk/duets/, accessed 10 July 2011).
SRs do not generally capture adverse effects or summarize
observational studies well. However, they have been used to
explore the possibility of advantageous unexpected side
effects (Dellavalle et al., 2005). Some reviews may be titled
‘‘systematic,’’ although their methods are not. Last, many SRs
are performed without input from patients, care givers, and
other lay healthcare consumers (Collier et al., 2005b).
FUTURE CHALLENGES FOR CER
Both SRs and their component RCTs aim to inform patient
care by discovering novel information using experimental
methods that strive to reduce bias. Similar to any other study
design, both are susceptible to abuse that can be overcome
by following the principles of prospective registration
(PROSPERO, http://www.crd.york.ac.uk/prospero/, accessed
22 July 2011, and ClinicTrials.gov, http://www.clinicaltrials.
gov/ct2/info/about, accessed 23 July 2011) and complete
reporting (PRISMA and CONSORT) (Schultz et al., 2010;
Tricco et al., 2011). Although the basic design of clinical
trials is likely to remain stable for many years, several
methodological aspects could develop further in dermatology
such as the use of cluster randomization for group interven-
tions (Naldi et al., 2007; Brierley et al., 2011), group
sequential methods for assessing interventions in resource-
poor situations ethically (Honigmann et al., 2007), large
simple trials (Peto et al., 1995), adaptive designs that may
increase study efficiency (Ozolins et al., 2004; Cook and
DeMets, 2010; Ke´rob et al., 2010), or the clinically integrated
randomized trial where trial outcomes are obtained from
routine clinical data (Vickers and Scardino, 2009). The
Cochrane Collaboration supports several methods groups
who are constantly striving to identify and incorporate
methodological advances into Cochrane SRs such as risk of
bias and summary of findings tables (Higgins and Green,
2011). Summarizing complex information on many interven-
tions is a challenge. Some Cochrane reviews are very large
(Mason et al., 2009), and visual depictions of evidence such
as balloon race diagrams may be one way forward to
summarize information in a more accessible way (http://
www.informationisbeautiful.net/visualizations/snake-oil-
supplements/, accessed 23 July 2011). Others are exploring
indirect methods for comparing several sources of data such
as network analysis or hierarchical modeling of different
types of data (Turner et al., 2001; Lu and Ades, 2004). Use of
Bayesian methods (Spiegelhalter et al., 2000) and decision
analytical modeling (such as decision analysis and Markov
modeling) for economic assessment is still relatively un-
common in dermatology (Petrou and Gray, 2011).
Reducing research waste is also a future priority by
addressing those features identified in Figure 4 (Chalmers and
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Figure 4. Research wastage can occur at several stages along the research development pathway. Reproduced with permission from Chalmers and Glasziou
(2009).
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Glasziou, 2009). Making all clinical trial data available in the
public domain and increasing transparency of potential
conflicts of interest are also desirable future goals (Rising
et al., 2008; Gøtzsche and Jørgensen, 2011). International
collections of trials organized by disease type such as the
GREAT (global resource of eczema trials) database are
another way of reducing duplicating searches for the same
data (Nankervis et al., 2011). Prioritizing new research can be
done by bringing patients, carers, and healthcare profes-
sionals together to consider which uncertainties derived from
SRs are both important and scientifically possible to answer.
Organizations such as the James Lind Alliance are pioneering
methods to bring such groups together (Eleftheriadou et al.,
2011). The final challenge is that of implementing important
study findings into clinical practice more rapidly, a major
focus for health services research discussed further by Chren
(2012) in this issue. Understanding how the results of studies
on groups of patients can be better applied to individuals is
also a conundrum that might unfold with personalized
medicine (Holmes et al., 2009). New healthcare interven-
tions can take 17 years to be adopted into practice
(Committee on Quality of Health Care in America, 2001).
Although some conservatism is probably healthy given the
withdrawal of some drugs that appear safe at first (Carson
et al., 2009), 17 years is clearly failing patients and society.
We must and can do better.
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